nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ALB—Fluorouracil—head and neck cancer	0.0902	0.214	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0738	0.175	CbGbCtD
Tacrolimus—CYP3A7—Docetaxel—head and neck cancer	0.0738	0.175	CbGbCtD
Tacrolimus—CYP3A5—Docetaxel—head and neck cancer	0.0554	0.132	CbGbCtD
Tacrolimus—ABCB1—Vinblastine—head and neck cancer	0.0437	0.104	CbGbCtD
Tacrolimus—ABCB1—Docetaxel—head and neck cancer	0.036	0.0857	CbGbCtD
Tacrolimus—CYP3A4—Vinblastine—head and neck cancer	0.0262	0.0623	CbGbCtD
Tacrolimus—CYP3A4—Docetaxel—head and neck cancer	0.0216	0.0513	CbGbCtD
Tacrolimus—ORM1—saliva—head and neck cancer	0.00663	0.0818	CbGeAlD
Tacrolimus—PPP3CA—hair follicle—head and neck cancer	0.00615	0.0758	CbGeAlD
Tacrolimus—ABCA5—parotid gland—head and neck cancer	0.00497	0.0613	CbGeAlD
Tacrolimus—ABCA5—saliva-secreting gland—head and neck cancer	0.00476	0.0587	CbGeAlD
Tacrolimus—ABCA5—trachea—head and neck cancer	0.00367	0.0453	CbGeAlD
Tacrolimus—PPP3CA—parotid gland—head and neck cancer	0.00336	0.0414	CbGeAlD
Tacrolimus—PPP3CA—saliva-secreting gland—head and neck cancer	0.00322	0.0397	CbGeAlD
Tacrolimus—MTOR—neck—head and neck cancer	0.00305	0.0376	CbGeAlD
Tacrolimus—PPP3CA—connective tissue—head and neck cancer	0.00296	0.0364	CbGeAlD
Tacrolimus—ABCA5—thyroid gland—head and neck cancer	0.00291	0.0358	CbGeAlD
Tacrolimus—FKBP1A—neck—head and neck cancer	0.00274	0.0338	CbGeAlD
Tacrolimus—ABCA5—head—head and neck cancer	0.00258	0.0318	CbGeAlD
Tacrolimus—PPP3CA—trachea—head and neck cancer	0.00248	0.0306	CbGeAlD
Tacrolimus—MTOR—connective tissue—head and neck cancer	0.00218	0.0269	CbGeAlD
Tacrolimus—PPP3CA—lymphoid tissue—head and neck cancer	0.00216	0.0266	CbGeAlD
Tacrolimus—MTOR—epithelium—head and neck cancer	0.00207	0.0256	CbGeAlD
Tacrolimus—FKBP1A—connective tissue—head and neck cancer	0.00196	0.0242	CbGeAlD
Tacrolimus—PPP3CA—thyroid gland—head and neck cancer	0.00196	0.0242	CbGeAlD
Tacrolimus—FKBP1A—epithelium—head and neck cancer	0.00186	0.023	CbGeAlD
Tacrolimus—ABCA5—lymph node—head and neck cancer	0.0018	0.0223	CbGeAlD
Tacrolimus—PPP3CA—head—head and neck cancer	0.00174	0.0215	CbGeAlD
Tacrolimus—FKBP1A—trachea—head and neck cancer	0.00165	0.0203	CbGeAlD
Tacrolimus—MTOR—lymphoid tissue—head and neck cancer	0.0016	0.0197	CbGeAlD
Tacrolimus—MTOR—thyroid gland—head and neck cancer	0.00145	0.0179	CbGeAlD
Tacrolimus—FKBP1A—lymphoid tissue—head and neck cancer	0.00144	0.0177	CbGeAlD
Tacrolimus—FKBP1A—thyroid gland—head and neck cancer	0.0013	0.0161	CbGeAlD
Tacrolimus—MTOR—head—head and neck cancer	0.00129	0.0159	CbGeAlD
Tacrolimus—PPP3CA—lymph node—head and neck cancer	0.00122	0.015	CbGeAlD
Tacrolimus—FKBP1A—head—head and neck cancer	0.00116	0.0143	CbGeAlD
Tacrolimus—MTOR—lymph node—head and neck cancer	0.000901	0.0111	CbGeAlD
Tacrolimus—FKBP1A—lymph node—head and neck cancer	0.00081	0.00999	CbGeAlD
Tacrolimus—Candida infection—Docetaxel—head and neck cancer	0.000681	0.00221	CcSEcCtD
Tacrolimus—Fluid retention—Docetaxel—head and neck cancer	0.000677	0.0022	CcSEcCtD
Tacrolimus—Neuropathy—Docetaxel—head and neck cancer	0.000669	0.00218	CcSEcCtD
Tacrolimus—Alopecia—Vinblastine—head and neck cancer	0.000668	0.00217	CcSEcCtD
Tacrolimus—Dry skin—Fluorouracil—head and neck cancer	0.000657	0.00214	CcSEcCtD
Tacrolimus—Oesophagitis—Docetaxel—head and neck cancer	0.000652	0.00212	CcSEcCtD
Tacrolimus—Neoplasm—Docetaxel—head and neck cancer	0.000645	0.0021	CcSEcCtD
Tacrolimus—Pulmonary oedema—Docetaxel—head and neck cancer	0.000635	0.00206	CcSEcCtD
Tacrolimus—ORM1—lymph node—head and neck cancer	0.000634	0.00782	CbGeAlD
Tacrolimus—Muscular weakness—Fluorouracil—head and neck cancer	0.000632	0.00206	CcSEcCtD
Tacrolimus—Angiopathy—Hydroxyurea—head and neck cancer	0.000625	0.00203	CcSEcCtD
Tacrolimus—Dysphagia—Fluorouracil—head and neck cancer	0.00062	0.00202	CcSEcCtD
Tacrolimus—Sepsis—Docetaxel—head and neck cancer	0.000619	0.00201	CcSEcCtD
Tacrolimus—Chills—Hydroxyurea—head and neck cancer	0.000618	0.00201	CcSEcCtD
Tacrolimus—Ill-defined disorder—Vinblastine—head and neck cancer	0.00061	0.00199	CcSEcCtD
Tacrolimus—Alopecia—Hydroxyurea—head and neck cancer	0.000609	0.00198	CcSEcCtD
Tacrolimus—Anaemia—Vinblastine—head and neck cancer	0.000608	0.00198	CcSEcCtD
Tacrolimus—Angina pectoris—Fluorouracil—head and neck cancer	0.000604	0.00196	CcSEcCtD
Tacrolimus—Phlebitis—Docetaxel—head and neck cancer	0.000601	0.00195	CcSEcCtD
Tacrolimus—Erythema—Hydroxyurea—head and neck cancer	0.0006	0.00195	CcSEcCtD
Tacrolimus—Thrombophlebitis—Docetaxel—head and neck cancer	0.000598	0.00194	CcSEcCtD
Tacrolimus—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000595	0.00194	CcSEcCtD
Tacrolimus—Malaise—Vinblastine—head and neck cancer	0.000593	0.00193	CcSEcCtD
Tacrolimus—Vertigo—Vinblastine—head and neck cancer	0.000591	0.00192	CcSEcCtD
Tacrolimus—Leukopenia—Vinblastine—head and neck cancer	0.000589	0.00192	CcSEcCtD
Tacrolimus—Pancytopenia—Fluorouracil—head and neck cancer	0.000589	0.00191	CcSEcCtD
Tacrolimus—Deafness—Docetaxel—head and neck cancer	0.000579	0.00188	CcSEcCtD
Tacrolimus—Hepatic failure—Docetaxel—head and neck cancer	0.000576	0.00187	CcSEcCtD
Tacrolimus—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000571	0.00186	CcSEcCtD
Tacrolimus—Convulsion—Vinblastine—head and neck cancer	0.00057	0.00185	CcSEcCtD
Tacrolimus—Hypertension—Vinblastine—head and neck cancer	0.000568	0.00185	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000566	0.00184	CcSEcCtD
Tacrolimus—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000557	0.00181	CcSEcCtD
Tacrolimus—ALB—lymph node—head and neck cancer	0.000556	0.00686	CbGeAlD
Tacrolimus—Pneumonia—Fluorouracil—head and neck cancer	0.000556	0.00181	CcSEcCtD
Tacrolimus—Anaemia—Hydroxyurea—head and neck cancer	0.000555	0.0018	CcSEcCtD
Tacrolimus—Discomfort—Vinblastine—head and neck cancer	0.000553	0.0018	CcSEcCtD
Tacrolimus—Hot flush—Docetaxel—head and neck cancer	0.000553	0.0018	CcSEcCtD
Tacrolimus—Infestation NOS—Fluorouracil—head and neck cancer	0.000553	0.0018	CcSEcCtD
Tacrolimus—Infestation—Fluorouracil—head and neck cancer	0.000553	0.0018	CcSEcCtD
Tacrolimus—Menopausal symptoms—Docetaxel—head and neck cancer	0.000549	0.00178	CcSEcCtD
Tacrolimus—Atrial fibrillation—Docetaxel—head and neck cancer	0.000546	0.00178	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000545	0.00177	CcSEcCtD
Tacrolimus—Renal impairment—Docetaxel—head and neck cancer	0.000544	0.00177	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000542	0.00176	CcSEcCtD
Tacrolimus—Myocardial infarction—Fluorouracil—head and neck cancer	0.000542	0.00176	CcSEcCtD
Tacrolimus—Dermatitis bullous—Docetaxel—head and neck cancer	0.000542	0.00176	CcSEcCtD
Tacrolimus—Malaise—Hydroxyurea—head and neck cancer	0.000541	0.00176	CcSEcCtD
Tacrolimus—Stomatitis—Fluorouracil—head and neck cancer	0.000539	0.00175	CcSEcCtD
Tacrolimus—Urinary tract infection—Fluorouracil—head and neck cancer	0.000537	0.00175	CcSEcCtD
Tacrolimus—Conjunctivitis—Fluorouracil—head and neck cancer	0.000537	0.00175	CcSEcCtD
Tacrolimus—Leukopenia—Hydroxyurea—head and neck cancer	0.000537	0.00175	CcSEcCtD
Tacrolimus—Cardiac failure—Docetaxel—head and neck cancer	0.00053	0.00173	CcSEcCtD
Tacrolimus—Thrombocytopenia—Vinblastine—head and neck cancer	0.000526	0.00171	CcSEcCtD
Tacrolimus—Epistaxis—Fluorouracil—head and neck cancer	0.000521	0.0017	CcSEcCtD
Tacrolimus—Convulsion—Hydroxyurea—head and neck cancer	0.00052	0.00169	CcSEcCtD
Tacrolimus—Hyponatraemia—Docetaxel—head and neck cancer	0.00052	0.00169	CcSEcCtD
Tacrolimus—Sinusitis—Fluorouracil—head and neck cancer	0.000518	0.00169	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000518	0.00168	CcSEcCtD
Tacrolimus—Pain in extremity—Docetaxel—head and neck cancer	0.000518	0.00168	CcSEcCtD
Tacrolimus—Agranulocytosis—Fluorouracil—head and neck cancer	0.000516	0.00168	CcSEcCtD
Tacrolimus—Anorexia—Vinblastine—head and neck cancer	0.000512	0.00166	CcSEcCtD
Tacrolimus—Migraine—Docetaxel—head and neck cancer	0.000509	0.00166	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000507	0.00165	CcSEcCtD
Tacrolimus—Discomfort—Hydroxyurea—head and neck cancer	0.000505	0.00164	CcSEcCtD
Tacrolimus—Haemoglobin—Fluorouracil—head and neck cancer	0.000499	0.00162	CcSEcCtD
Tacrolimus—Rhinitis—Fluorouracil—head and neck cancer	0.000497	0.00162	CcSEcCtD
Tacrolimus—Haemorrhage—Fluorouracil—head and neck cancer	0.000496	0.00161	CcSEcCtD
Tacrolimus—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000494	0.00161	CcSEcCtD
Tacrolimus—Pharyngitis—Fluorouracil—head and neck cancer	0.000492	0.0016	CcSEcCtD
Tacrolimus—Oedema—Hydroxyurea—head and neck cancer	0.00049	0.00159	CcSEcCtD
Tacrolimus—Infection—Hydroxyurea—head and neck cancer	0.000486	0.00158	CcSEcCtD
Tacrolimus—Paraesthesia—Vinblastine—head and neck cancer	0.000482	0.00157	CcSEcCtD
Tacrolimus—Dehydration—Docetaxel—head and neck cancer	0.000481	0.00157	CcSEcCtD
Tacrolimus—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00048	0.00156	CcSEcCtD
Tacrolimus—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000479	0.00156	CcSEcCtD
Tacrolimus—Liver function test abnormal—Docetaxel—head and neck cancer	0.000478	0.00155	CcSEcCtD
Tacrolimus—Skin disorder—Hydroxyurea—head and neck cancer	0.000476	0.00155	CcSEcCtD
Tacrolimus—Dry skin—Docetaxel—head and neck cancer	0.000474	0.00154	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000473	0.00154	CcSEcCtD
Tacrolimus—Breast disorder—Docetaxel—head and neck cancer	0.000468	0.00152	CcSEcCtD
Tacrolimus—Anorexia—Hydroxyurea—head and neck cancer	0.000467	0.00152	CcSEcCtD
Tacrolimus—Decreased appetite—Vinblastine—head and neck cancer	0.000467	0.00152	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000466	0.00152	CcSEcCtD
Tacrolimus—Cramp muscle—Docetaxel—head and neck cancer	0.000466	0.00152	CcSEcCtD
Tacrolimus—Constipation—Vinblastine—head and neck cancer	0.000459	0.00149	CcSEcCtD
Tacrolimus—Pain—Vinblastine—head and neck cancer	0.000459	0.00149	CcSEcCtD
Tacrolimus—Dysphagia—Docetaxel—head and neck cancer	0.000447	0.00146	CcSEcCtD
Tacrolimus—Arrhythmia—Fluorouracil—head and neck cancer	0.000443	0.00144	CcSEcCtD
Tacrolimus—Feeling abnormal—Vinblastine—head and neck cancer	0.000442	0.00144	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000439	0.00143	CcSEcCtD
Tacrolimus—Alopecia—Fluorouracil—head and neck cancer	0.000438	0.00143	CcSEcCtD
Tacrolimus—Dyspnoea—Hydroxyurea—head and neck cancer	0.000437	0.00142	CcSEcCtD
Tacrolimus—Angina pectoris—Docetaxel—head and neck cancer	0.000436	0.00142	CcSEcCtD
Tacrolimus—Somnolence—Hydroxyurea—head and neck cancer	0.000435	0.00142	CcSEcCtD
Tacrolimus—Erythema—Fluorouracil—head and neck cancer	0.000432	0.0014	CcSEcCtD
Tacrolimus—ABCB1—epithelium—head and neck cancer	0.000431	0.00532	CbGeAlD
Tacrolimus—Dyspepsia—Hydroxyurea—head and neck cancer	0.000431	0.0014	CcSEcCtD
Tacrolimus—Decreased appetite—Hydroxyurea—head and neck cancer	0.000426	0.00138	CcSEcCtD
Tacrolimus—Pancytopenia—Docetaxel—head and neck cancer	0.000425	0.00138	CcSEcCtD
Tacrolimus—Abdominal pain—Vinblastine—head and neck cancer	0.000424	0.00138	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000423	0.00138	CcSEcCtD
Tacrolimus—Fatigue—Hydroxyurea—head and neck cancer	0.000422	0.00137	CcSEcCtD
Tacrolimus—Pain—Hydroxyurea—head and neck cancer	0.000419	0.00136	CcSEcCtD
Tacrolimus—Constipation—Hydroxyurea—head and neck cancer	0.000419	0.00136	CcSEcCtD
Tacrolimus—Neutropenia—Docetaxel—head and neck cancer	0.000418	0.00136	CcSEcCtD
Tacrolimus—Weight increased—Docetaxel—head and neck cancer	0.000407	0.00132	CcSEcCtD
Tacrolimus—Vision blurred—Fluorouracil—head and neck cancer	0.000407	0.00132	CcSEcCtD
Tacrolimus—Weight decreased—Docetaxel—head and neck cancer	0.000405	0.00132	CcSEcCtD
Tacrolimus—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000404	0.00131	CcSEcCtD
Tacrolimus—Pneumonia—Docetaxel—head and neck cancer	0.000401	0.0013	CcSEcCtD
Tacrolimus—Anaemia—Fluorouracil—head and neck cancer	0.000399	0.0013	CcSEcCtD
Tacrolimus—Infestation NOS—Docetaxel—head and neck cancer	0.000399	0.0013	CcSEcCtD
Tacrolimus—Infestation—Docetaxel—head and neck cancer	0.000399	0.0013	CcSEcCtD
Tacrolimus—Hypersensitivity—Vinblastine—head and neck cancer	0.000396	0.00129	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000395	0.00129	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000393	0.00128	CcSEcCtD
Tacrolimus—Renal failure—Docetaxel—head and neck cancer	0.000392	0.00128	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000391	0.00127	CcSEcCtD
Tacrolimus—Myocardial infarction—Docetaxel—head and neck cancer	0.000391	0.00127	CcSEcCtD
Tacrolimus—Stomatitis—Docetaxel—head and neck cancer	0.000389	0.00126	CcSEcCtD
Tacrolimus—Jaundice—Docetaxel—head and neck cancer	0.000389	0.00126	CcSEcCtD
Tacrolimus—Conjunctivitis—Docetaxel—head and neck cancer	0.000388	0.00126	CcSEcCtD
Tacrolimus—Body temperature increased—Hydroxyurea—head and neck cancer	0.000387	0.00126	CcSEcCtD
Tacrolimus—Leukopenia—Fluorouracil—head and neck cancer	0.000387	0.00126	CcSEcCtD
Tacrolimus—Asthenia—Vinblastine—head and neck cancer	0.000385	0.00125	CcSEcCtD
Tacrolimus—ABCB1—trachea—head and neck cancer	0.000381	0.0047	CbGeAlD
Tacrolimus—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000377	0.00123	CcSEcCtD
Tacrolimus—Epistaxis—Docetaxel—head and neck cancer	0.000376	0.00122	CcSEcCtD
Tacrolimus—Convulsion—Fluorouracil—head and neck cancer	0.000374	0.00122	CcSEcCtD
Tacrolimus—Agranulocytosis—Docetaxel—head and neck cancer	0.000372	0.00121	CcSEcCtD
Tacrolimus—Chest pain—Fluorouracil—head and neck cancer	0.000368	0.0012	CcSEcCtD
Tacrolimus—Myalgia—Fluorouracil—head and neck cancer	0.000368	0.0012	CcSEcCtD
Tacrolimus—Diarrhoea—Vinblastine—head and neck cancer	0.000367	0.00119	CcSEcCtD
Tacrolimus—Discomfort—Fluorouracil—head and neck cancer	0.000363	0.00118	CcSEcCtD
Tacrolimus—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000361	0.00117	CcSEcCtD
Tacrolimus—Haemoglobin—Docetaxel—head and neck cancer	0.00036	0.00117	CcSEcCtD
Tacrolimus—Rhinitis—Docetaxel—head and neck cancer	0.000359	0.00117	CcSEcCtD
Tacrolimus—Haemorrhage—Docetaxel—head and neck cancer	0.000358	0.00116	CcSEcCtD
Tacrolimus—Hepatitis—Docetaxel—head and neck cancer	0.000358	0.00116	CcSEcCtD
Tacrolimus—Hypoaesthesia—Docetaxel—head and neck cancer	0.000356	0.00116	CcSEcCtD
Tacrolimus—Confusional state—Fluorouracil—head and neck cancer	0.000355	0.00116	CcSEcCtD
Tacrolimus—Pharyngitis—Docetaxel—head and neck cancer	0.000355	0.00116	CcSEcCtD
Tacrolimus—Dizziness—Vinblastine—head and neck cancer	0.000355	0.00115	CcSEcCtD
Tacrolimus—Urinary tract disorder—Docetaxel—head and neck cancer	0.000354	0.00115	CcSEcCtD
Tacrolimus—Oedema peripheral—Docetaxel—head and neck cancer	0.000353	0.00115	CcSEcCtD
Tacrolimus—Oedema—Fluorouracil—head and neck cancer	0.000352	0.00115	CcSEcCtD
Tacrolimus—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000352	0.00115	CcSEcCtD
Tacrolimus—Connective tissue disorder—Docetaxel—head and neck cancer	0.000352	0.00114	CcSEcCtD
Tacrolimus—Asthenia—Hydroxyurea—head and neck cancer	0.000351	0.00114	CcSEcCtD
Tacrolimus—Urethral disorder—Docetaxel—head and neck cancer	0.000351	0.00114	CcSEcCtD
Tacrolimus—Infection—Fluorouracil—head and neck cancer	0.00035	0.00114	CcSEcCtD
Tacrolimus—Nervous system disorder—Fluorouracil—head and neck cancer	0.000346	0.00112	CcSEcCtD
Tacrolimus—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000345	0.00112	CcSEcCtD
Tacrolimus—Visual impairment—Docetaxel—head and neck cancer	0.000345	0.00112	CcSEcCtD
Tacrolimus—Tachycardia—Fluorouracil—head and neck cancer	0.000344	0.00112	CcSEcCtD
Tacrolimus—Vomiting—Vinblastine—head and neck cancer	0.000341	0.00111	CcSEcCtD
Tacrolimus—Erythema multiforme—Docetaxel—head and neck cancer	0.000339	0.0011	CcSEcCtD
Tacrolimus—Headache—Vinblastine—head and neck cancer	0.000336	0.00109	CcSEcCtD
Tacrolimus—Anorexia—Fluorouracil—head and neck cancer	0.000336	0.00109	CcSEcCtD
Tacrolimus—Diarrhoea—Hydroxyurea—head and neck cancer	0.000335	0.00109	CcSEcCtD
Tacrolimus—Eye disorder—Docetaxel—head and neck cancer	0.000335	0.00109	CcSEcCtD
Tacrolimus—Cardiac disorder—Docetaxel—head and neck cancer	0.000332	0.00108	CcSEcCtD
Tacrolimus—Flushing—Docetaxel—head and neck cancer	0.000332	0.00108	CcSEcCtD
Tacrolimus—ABCB1—lymphoid tissue—head and neck cancer	0.000332	0.00409	CbGeAlD
Tacrolimus—Hypotension—Fluorouracil—head and neck cancer	0.000329	0.00107	CcSEcCtD
Tacrolimus—Angiopathy—Docetaxel—head and neck cancer	0.000325	0.00106	CcSEcCtD
Tacrolimus—Dizziness—Hydroxyurea—head and neck cancer	0.000324	0.00105	CcSEcCtD
Tacrolimus—Immune system disorder—Docetaxel—head and neck cancer	0.000323	0.00105	CcSEcCtD
Tacrolimus—Mediastinal disorder—Docetaxel—head and neck cancer	0.000323	0.00105	CcSEcCtD
Tacrolimus—Chills—Docetaxel—head and neck cancer	0.000321	0.00105	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000321	0.00104	CcSEcCtD
Tacrolimus—Arrhythmia—Docetaxel—head and neck cancer	0.00032	0.00104	CcSEcCtD
Tacrolimus—Nausea—Vinblastine—head and neck cancer	0.000319	0.00104	CcSEcCtD
Tacrolimus—Insomnia—Fluorouracil—head and neck cancer	0.000319	0.00104	CcSEcCtD
Tacrolimus—Paraesthesia—Fluorouracil—head and neck cancer	0.000316	0.00103	CcSEcCtD
Tacrolimus—Alopecia—Docetaxel—head and neck cancer	0.000316	0.00103	CcSEcCtD
Tacrolimus—Dyspnoea—Fluorouracil—head and neck cancer	0.000314	0.00102	CcSEcCtD
Tacrolimus—Mental disorder—Docetaxel—head and neck cancer	0.000314	0.00102	CcSEcCtD
Tacrolimus—Somnolence—Fluorouracil—head and neck cancer	0.000313	0.00102	CcSEcCtD
Tacrolimus—Erythema—Docetaxel—head and neck cancer	0.000312	0.00101	CcSEcCtD
Tacrolimus—Malnutrition—Docetaxel—head and neck cancer	0.000312	0.00101	CcSEcCtD
Tacrolimus—Vomiting—Hydroxyurea—head and neck cancer	0.000311	0.00101	CcSEcCtD
Tacrolimus—Dyspepsia—Fluorouracil—head and neck cancer	0.00031	0.00101	CcSEcCtD
Tacrolimus—Rash—Hydroxyurea—head and neck cancer	0.000309	0.001	CcSEcCtD
Tacrolimus—Dermatitis—Hydroxyurea—head and neck cancer	0.000308	0.001	CcSEcCtD
Tacrolimus—Headache—Hydroxyurea—head and neck cancer	0.000307	0.000998	CcSEcCtD
Tacrolimus—Decreased appetite—Fluorouracil—head and neck cancer	0.000306	0.000997	CcSEcCtD
Tacrolimus—Dysgeusia—Docetaxel—head and neck cancer	0.000305	0.000993	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000304	0.00099	CcSEcCtD
Tacrolimus—ABCB1—thyroid gland—head and neck cancer	0.000302	0.00372	CbGeAlD
Tacrolimus—Back pain—Docetaxel—head and neck cancer	0.000302	0.000981	CcSEcCtD
Tacrolimus—Pain—Fluorouracil—head and neck cancer	0.000301	0.00098	CcSEcCtD
Tacrolimus—Muscle spasms—Docetaxel—head and neck cancer	0.0003	0.000975	CcSEcCtD
Tacrolimus—Nausea—Hydroxyurea—head and neck cancer	0.000291	0.000946	CcSEcCtD
Tacrolimus—Feeling abnormal—Fluorouracil—head and neck cancer	0.00029	0.000945	CcSEcCtD
Tacrolimus—Anaemia—Docetaxel—head and neck cancer	0.000288	0.000937	CcSEcCtD
Tacrolimus—Urticaria—Fluorouracil—head and neck cancer	0.00028	0.000911	CcSEcCtD
Tacrolimus—Syncope—Docetaxel—head and neck cancer	0.00028	0.000909	CcSEcCtD
Tacrolimus—Leukopenia—Docetaxel—head and neck cancer	0.000279	0.000908	CcSEcCtD
Tacrolimus—Body temperature increased—Fluorouracil—head and neck cancer	0.000279	0.000906	CcSEcCtD
Tacrolimus—Palpitations—Docetaxel—head and neck cancer	0.000275	0.000896	CcSEcCtD
Tacrolimus—Loss of consciousness—Docetaxel—head and neck cancer	0.000274	0.000891	CcSEcCtD
Tacrolimus—Cough—Docetaxel—head and neck cancer	0.000272	0.000885	CcSEcCtD
Tacrolimus—Convulsion—Docetaxel—head and neck cancer	0.00027	0.000878	CcSEcCtD
Tacrolimus—Hypertension—Docetaxel—head and neck cancer	0.000269	0.000875	CcSEcCtD
Tacrolimus—ABCB1—head—head and neck cancer	0.000268	0.0033	CbGeAlD
Tacrolimus—Chest pain—Docetaxel—head and neck cancer	0.000265	0.000863	CcSEcCtD
Tacrolimus—Myalgia—Docetaxel—head and neck cancer	0.000265	0.000863	CcSEcCtD
Tacrolimus—Arthralgia—Docetaxel—head and neck cancer	0.000265	0.000863	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000264	0.000857	CcSEcCtD
Tacrolimus—Hypersensitivity—Fluorouracil—head and neck cancer	0.00026	0.000845	CcSEcCtD
Tacrolimus—Dry mouth—Docetaxel—head and neck cancer	0.00026	0.000844	CcSEcCtD
Tacrolimus—Confusional state—Docetaxel—head and neck cancer	0.000257	0.000834	CcSEcCtD
Tacrolimus—Oedema—Docetaxel—head and neck cancer	0.000254	0.000827	CcSEcCtD
Tacrolimus—Anaphylactic shock—Docetaxel—head and neck cancer	0.000254	0.000827	CcSEcCtD
Tacrolimus—Infection—Docetaxel—head and neck cancer	0.000253	0.000822	CcSEcCtD
Tacrolimus—Shock—Docetaxel—head and neck cancer	0.00025	0.000814	CcSEcCtD
Tacrolimus—Nervous system disorder—Docetaxel—head and neck cancer	0.000249	0.000811	CcSEcCtD
Tacrolimus—Pruritus—Fluorouracil—head and neck cancer	0.000249	0.000811	CcSEcCtD
Tacrolimus—Thrombocytopenia—Docetaxel—head and neck cancer	0.000249	0.00081	CcSEcCtD
Tacrolimus—Tachycardia—Docetaxel—head and neck cancer	0.000248	0.000808	CcSEcCtD
Tacrolimus—Skin disorder—Docetaxel—head and neck cancer	0.000247	0.000804	CcSEcCtD
Tacrolimus—Anorexia—Docetaxel—head and neck cancer	0.000242	0.000789	CcSEcCtD
Tacrolimus—Diarrhoea—Fluorouracil—head and neck cancer	0.000241	0.000784	CcSEcCtD
Tacrolimus—Hypotension—Docetaxel—head and neck cancer	0.000238	0.000773	CcSEcCtD
Tacrolimus—Dizziness—Fluorouracil—head and neck cancer	0.000233	0.000758	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000232	0.000754	CcSEcCtD
Tacrolimus—Insomnia—Docetaxel—head and neck cancer	0.00023	0.000748	CcSEcCtD
Tacrolimus—Paraesthesia—Docetaxel—head and neck cancer	0.000228	0.000743	CcSEcCtD
Tacrolimus—Dyspnoea—Docetaxel—head and neck cancer	0.000227	0.000738	CcSEcCtD
Tacrolimus—Somnolence—Docetaxel—head and neck cancer	0.000226	0.000736	CcSEcCtD
Tacrolimus—Vomiting—Fluorouracil—head and neck cancer	0.000224	0.000729	CcSEcCtD
Tacrolimus—Dyspepsia—Docetaxel—head and neck cancer	0.000224	0.000728	CcSEcCtD
Tacrolimus—Rash—Fluorouracil—head and neck cancer	0.000222	0.000723	CcSEcCtD
Tacrolimus—Dermatitis—Fluorouracil—head and neck cancer	0.000222	0.000722	CcSEcCtD
Tacrolimus—Decreased appetite—Docetaxel—head and neck cancer	0.000221	0.000719	CcSEcCtD
Tacrolimus—Headache—Fluorouracil—head and neck cancer	0.000221	0.000718	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00022	0.000714	CcSEcCtD
Tacrolimus—Fatigue—Docetaxel—head and neck cancer	0.000219	0.000713	CcSEcCtD
Tacrolimus—Pain—Docetaxel—head and neck cancer	0.000218	0.000708	CcSEcCtD
Tacrolimus—Constipation—Docetaxel—head and neck cancer	0.000218	0.000708	CcSEcCtD
Tacrolimus—Feeling abnormal—Docetaxel—head and neck cancer	0.00021	0.000682	CcSEcCtD
Tacrolimus—Nausea—Fluorouracil—head and neck cancer	0.000209	0.000681	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000208	0.000677	CcSEcCtD
Tacrolimus—Abdominal pain—Docetaxel—head and neck cancer	0.000201	0.000654	CcSEcCtD
Tacrolimus—Body temperature increased—Docetaxel—head and neck cancer	0.000201	0.000654	CcSEcCtD
Tacrolimus—Hypersensitivity—Docetaxel—head and neck cancer	0.000187	0.00061	CcSEcCtD
Tacrolimus—ABCB1—lymph node—head and neck cancer	0.000187	0.00231	CbGeAlD
Tacrolimus—Asthenia—Docetaxel—head and neck cancer	0.000183	0.000594	CcSEcCtD
Tacrolimus—Pruritus—Docetaxel—head and neck cancer	0.00018	0.000585	CcSEcCtD
Tacrolimus—Diarrhoea—Docetaxel—head and neck cancer	0.000174	0.000566	CcSEcCtD
Tacrolimus—Dizziness—Docetaxel—head and neck cancer	0.000168	0.000547	CcSEcCtD
Tacrolimus—Vomiting—Docetaxel—head and neck cancer	0.000162	0.000526	CcSEcCtD
Tacrolimus—Rash—Docetaxel—head and neck cancer	0.00016	0.000522	CcSEcCtD
Tacrolimus—Dermatitis—Docetaxel—head and neck cancer	0.00016	0.000521	CcSEcCtD
Tacrolimus—Headache—Docetaxel—head and neck cancer	0.000159	0.000518	CcSEcCtD
Tacrolimus—Nausea—Docetaxel—head and neck cancer	0.000151	0.000491	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—VEGFA—head and neck cancer	9.85e-05	0.000516	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	9.82e-05	0.000515	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—PIK3CA—head and neck cancer	9.8e-05	0.000513	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	9.8e-05	0.000513	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—HRAS—head and neck cancer	9.8e-05	0.000513	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HRAS—head and neck cancer	9.8e-05	0.000513	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—AKT1—head and neck cancer	9.77e-05	0.000512	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—STAT3—head and neck cancer	9.75e-05	0.000511	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—HRAS—head and neck cancer	9.71e-05	0.000509	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—head and neck cancer	9.62e-05	0.000504	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—HRAS—head and neck cancer	9.58e-05	0.000502	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—PIK3CA—head and neck cancer	9.44e-05	0.000494	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—BCL2—head and neck cancer	9.4e-05	0.000493	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	9.38e-05	0.000491	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—AKT1—head and neck cancer	9.38e-05	0.000491	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—AKT1—head and neck cancer	9.33e-05	0.000489	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—MAPK3—head and neck cancer	9.32e-05	0.000488	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	9.29e-05	0.000487	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—AKT1—head and neck cancer	9.29e-05	0.000487	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—AKT1—head and neck cancer	9.24e-05	0.000484	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—AKT1—head and neck cancer	9.2e-05	0.000482	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—STAT3—head and neck cancer	9.15e-05	0.000479	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—HRAS—head and neck cancer	9.07e-05	0.000475	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—head and neck cancer	9.06e-05	0.000475	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2—head and neck cancer	9.06e-05	0.000475	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—MAPK1—head and neck cancer	8.86e-05	0.000464	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GRP—head and neck cancer	8.76e-05	0.000459	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—MAPK3—head and neck cancer	8.74e-05	0.000458	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HRAS—head and neck cancer	8.73e-05	0.000457	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	8.68e-05	0.000455	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	8.65e-05	0.000453	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—AKT1—head and neck cancer	8.65e-05	0.000453	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—AKT1—head and neck cancer	8.65e-05	0.000453	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NOTCH1—head and neck cancer	8.61e-05	0.000451	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—AKT1—head and neck cancer	8.57e-05	0.000449	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	8.55e-05	0.000448	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NAT2—head and neck cancer	8.54e-05	0.000447	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT6—head and neck cancer	8.5e-05	0.000446	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—head and neck cancer	8.5e-05	0.000445	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—AKT1—head and neck cancer	8.46e-05	0.000443	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—MAPK1—head and neck cancer	8.31e-05	0.000436	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—EGFR—head and neck cancer	8.31e-05	0.000436	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	8.29e-05	0.000434	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2—head and neck cancer	8.28e-05	0.000434	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—head and neck cancer	8.25e-05	0.000432	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CASP8—head and neck cancer	8.2e-05	0.00043	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	8.2e-05	0.00043	CbGpPWpGaD
Tacrolimus—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	8.17e-05	0.000428	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—AKT1—head and neck cancer	8.01e-05	0.000419	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	7.86e-05	0.000412	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PTEN—head and neck cancer	7.79e-05	0.000408	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CDH1—head and neck cancer	7.79e-05	0.000408	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NOTCH1—head and neck cancer	7.78e-05	0.000408	CbGpPWpGaD
Tacrolimus—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	7.75e-05	0.000406	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—AKT1—head and neck cancer	7.71e-05	0.000404	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	7.66e-05	0.000401	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—YAP1—head and neck cancer	7.53e-05	0.000394	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—DPYD—head and neck cancer	7.49e-05	0.000392	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—head and neck cancer	7.44e-05	0.00039	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	7.34e-05	0.000385	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—MAPK3—head and neck cancer	7.29e-05	0.000382	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—PIK3CA—head and neck cancer	7.21e-05	0.000378	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTEN—head and neck cancer	7.19e-05	0.000377	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—YAP1—head and neck cancer	7.1e-05	0.000372	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—BCL2—head and neck cancer	7.04e-05	0.000369	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.97e-05	0.000365	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—STAT3—head and neck cancer	6.97e-05	0.000365	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—MAPK1—head and neck cancer	6.93e-05	0.000363	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EGFR—head and neck cancer	6.93e-05	0.000363	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—UROD—head and neck cancer	6.91e-05	0.000362	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—HRAS—head and neck cancer	6.67e-05	0.00035	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—MAPK3—head and neck cancer	6.66e-05	0.000349	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	6.56e-05	0.000344	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—STAT3—head and neck cancer	6.43e-05	0.000337	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—head and neck cancer	6.4e-05	0.000335	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—MAPK1—head and neck cancer	6.33e-05	0.000332	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—head and neck cancer	6.33e-05	0.000332	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	6.3e-05	0.00033	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NAT2—head and neck cancer	6.17e-05	0.000323	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MAPK3—head and neck cancer	6.15e-05	0.000322	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	6.08e-05	0.000319	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NOTCH1—head and neck cancer	6.03e-05	0.000316	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PIK3CA—head and neck cancer	6.02e-05	0.000315	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—AKT1—head and neck cancer	5.89e-05	0.000309	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MAPK1—head and neck cancer	5.85e-05	0.000306	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—head and neck cancer	5.85e-05	0.000306	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—BCL2L1—head and neck cancer	5.85e-05	0.000306	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PTEN—head and neck cancer	5.83e-05	0.000306	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.65e-05	0.000296	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PTEN—head and neck cancer	5.6e-05	0.000293	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.59e-05	0.000293	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	5.58e-05	0.000292	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTEN—head and neck cancer	5.58e-05	0.000292	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—head and neck cancer	5.57e-05	0.000292	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PIK3CA—head and neck cancer	5.5e-05	0.000288	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.49e-05	0.000288	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—DPYD—head and neck cancer	5.41e-05	0.000284	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2—head and neck cancer	5.35e-05	0.00028	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NAT2—head and neck cancer	5.32e-05	0.000278	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	5.28e-05	0.000276	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCND1—head and neck cancer	5.22e-05	0.000273	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	5.2e-05	0.000272	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—YAP1—head and neck cancer	5.14e-05	0.000269	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—head and neck cancer	5.08e-05	0.000266	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PIK3CA—head and neck cancer	5.07e-05	0.000266	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTEN—head and neck cancer	5.04e-05	0.000264	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	5.02e-05	0.000263	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—STAT3—head and neck cancer	4.99e-05	0.000261	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MAPK3—head and neck cancer	4.98e-05	0.000261	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.94e-05	0.000259	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.94e-05	0.000259	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—head and neck cancer	4.91e-05	0.000257	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOTCH1—head and neck cancer	4.84e-05	0.000254	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CASP8—head and neck cancer	4.78e-05	0.00025	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MAPK3—head and neck cancer	4.77e-05	0.00025	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MAPK1—head and neck cancer	4.74e-05	0.000248	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—head and neck cancer	4.74e-05	0.000248	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDH1—head and neck cancer	4.72e-05	0.000247	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—head and neck cancer	4.69e-05	0.000246	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—DPYD—head and neck cancer	4.66e-05	0.000244	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NAT2—head and neck cancer	4.66e-05	0.000244	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—head and neck cancer	4.55e-05	0.000239	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—head and neck cancer	4.55e-05	0.000238	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MAPK1—head and neck cancer	4.53e-05	0.000238	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—head and neck cancer	4.53e-05	0.000238	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—head and neck cancer	4.5e-05	0.000236	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—head and neck cancer	4.49e-05	0.000235	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—YAP1—head and neck cancer	4.42e-05	0.000232	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	4.36e-05	0.000228	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MAPK3—head and neck cancer	4.3e-05	0.000225	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	4.29e-05	0.000225	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TYMS—head and neck cancer	4.27e-05	0.000224	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTM1—head and neck cancer	4.22e-05	0.000221	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—head and neck cancer	4.15e-05	0.000217	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	4.15e-05	0.000217	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—head and neck cancer	4.15e-05	0.000217	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—head and neck cancer	4.12e-05	0.000216	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—BCL2—head and neck cancer	4.1e-05	0.000215	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MAPK1—head and neck cancer	4.1e-05	0.000215	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—head and neck cancer	4.09e-05	0.000214	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—DPYD—head and neck cancer	4.08e-05	0.000214	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—head and neck cancer	4.05e-05	0.000212	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GPX1—head and neck cancer	4.04e-05	0.000212	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP1A1—head and neck cancer	4e-05	0.000209	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—head and neck cancer	3.95e-05	0.000207	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—head and neck cancer	3.93e-05	0.000206	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTEN—head and neck cancer	3.91e-05	0.000205	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—YAP1—head and neck cancer	3.88e-05	0.000203	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—head and neck cancer	3.81e-05	0.000199	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—head and neck cancer	3.66e-05	0.000192	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—head and neck cancer	3.64e-05	0.000191	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—head and neck cancer	3.61e-05	0.000189	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—head and neck cancer	3.6e-05	0.000188	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	3.56e-05	0.000186	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—head and neck cancer	3.55e-05	0.000186	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—head and neck cancer	3.53e-05	0.000185	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.5e-05	0.000184	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—head and neck cancer	3.49e-05	0.000183	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—head and neck cancer	3.44e-05	0.00018	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—head and neck cancer	3.4e-05	0.000178	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH1—head and neck cancer	3.39e-05	0.000178	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—head and neck cancer	3.38e-05	0.000177	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—head and neck cancer	3.36e-05	0.000176	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK3—head and neck cancer	3.34e-05	0.000175	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.32e-05	0.000174	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—head and neck cancer	3.29e-05	0.000172	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—head and neck cancer	3.23e-05	0.000169	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—head and neck cancer	3.21e-05	0.000168	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK1—head and neck cancer	3.18e-05	0.000166	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—head and neck cancer	3.17e-05	0.000166	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—head and neck cancer	3.14e-05	0.000164	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TYMS—head and neck cancer	3.08e-05	0.000162	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTM1—head and neck cancer	3.05e-05	0.00016	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—head and neck cancer	3.04e-05	0.000159	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GPX1—head and neck cancer	2.92e-05	0.000153	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—head and neck cancer	2.9e-05	0.000152	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK3—head and neck cancer	2.9e-05	0.000152	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.9e-05	0.000152	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP1A1—head and neck cancer	2.89e-05	0.000151	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—head and neck cancer	2.88e-05	0.000151	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NAT2—head and neck cancer	2.87e-05	0.00015	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—head and neck cancer	2.81e-05	0.000147	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK1—head and neck cancer	2.76e-05	0.000145	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—head and neck cancer	2.76e-05	0.000145	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—head and neck cancer	2.76e-05	0.000144	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—MAPK3—head and neck cancer	2.72e-05	0.000143	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAPK3—head and neck cancer	2.68e-05	0.00014	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—head and neck cancer	2.67e-05	0.00014	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TYMS—head and neck cancer	2.66e-05	0.000139	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTM1—head and neck cancer	2.63e-05	0.000138	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—MAPK1—head and neck cancer	2.59e-05	0.000136	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAPK1—head and neck cancer	2.55e-05	0.000134	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—head and neck cancer	2.55e-05	0.000134	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—head and neck cancer	2.55e-05	0.000134	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—DPYD—head and neck cancer	2.52e-05	0.000132	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GPX1—head and neck cancer	2.51e-05	0.000132	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP1A1—head and neck cancer	2.49e-05	0.00013	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—head and neck cancer	2.4e-05	0.000126	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—YAP1—head and neck cancer	2.39e-05	0.000125	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—head and neck cancer	2.38e-05	0.000125	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—head and neck cancer	2.33e-05	0.000122	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMS—head and neck cancer	2.33e-05	0.000122	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTM1—head and neck cancer	2.3e-05	0.000121	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—head and neck cancer	2.28e-05	0.000119	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—head and neck cancer	2.25e-05	0.000118	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—head and neck cancer	2.25e-05	0.000118	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—head and neck cancer	2.22e-05	0.000116	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—head and neck cancer	2.21e-05	0.000116	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GPX1—head and neck cancer	2.2e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—head and neck cancer	2.2e-05	0.000115	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.18e-05	0.000114	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—head and neck cancer	2.17e-05	0.000114	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—head and neck cancer	2.08e-05	0.000109	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—head and neck cancer	2.07e-05	0.000109	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—head and neck cancer	2.05e-05	0.000107	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.04e-05	0.000107	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—head and neck cancer	1.98e-05	0.000104	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—head and neck cancer	1.96e-05	0.000103	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—head and neck cancer	1.96e-05	0.000103	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK3—head and neck cancer	1.88e-05	9.83e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—head and neck cancer	1.83e-05	9.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—head and neck cancer	1.81e-05	9.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK1—head and neck cancer	1.79e-05	9.36e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—head and neck cancer	1.79e-05	9.35e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.72e-05	9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—head and neck cancer	1.55e-05	8.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—head and neck cancer	1.5e-05	7.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—head and neck cancer	1.5e-05	7.85e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—head and neck cancer	1.48e-05	7.75e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—head and neck cancer	1.46e-05	7.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMS—head and neck cancer	1.43e-05	7.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—head and neck cancer	1.43e-05	7.51e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.42e-05	7.42e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPX1—head and neck cancer	1.36e-05	7.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.34e-05	7.04e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—head and neck cancer	1.3e-05	6.79e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—head and neck cancer	1.29e-05	6.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—head and neck cancer	1.27e-05	6.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—head and neck cancer	1.19e-05	6.26e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—head and neck cancer	1.13e-05	5.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—head and neck cancer	1.06e-05	5.54e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—head and neck cancer	9.11e-06	4.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—head and neck cancer	8.64e-06	4.52e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—head and neck cancer	7.99e-06	4.19e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—head and neck cancer	7.98e-06	4.18e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—head and neck cancer	7.44e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—head and neck cancer	6.97e-06	3.65e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—head and neck cancer	6.52e-06	3.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.92e-06	2.58e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—head and neck cancer	4.02e-06	2.1e-05	CbGpPWpGaD
